Anticancer Fund

Tweet this page
<
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 13 May 2022
How to read and use this data card.
Download this datacard

Overview

Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

Lobbying Costs

None declared

Financial year: Jan 2021 - Dec 2021

Lobbyists (Full time equivalent)

0.75 Fte (2)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Anticancer Fund   (ACF)

    EU Transparency Register

    404359320127-95 First registered on 30 Dec 2015

    Goals / Remit

    The Anticancer Fund is dedicated to expanding the range of treatment options available to patients, regardless of their commercial value.
    The Anticancer Fund is a foundation of public utility with an international reach that focuses on the cure of cancer patients by:
    - Developing promising cancer treatments that are currently neglected and bringing the most valuable treatments to the patient as quickly as possible.
    - Providing free comprehensive, evidence-based information about cancer treatments.

    Main EU files targeted

    Main EU legislative proposals or policies targeted:
    Europe’s Beating Cancer Plan
    Horizon and the Cancer Mission
    New Pharmaceutical Strategy
    Special Committee on Cancer (BECA)
    MAC Group (Members of Parliament Against Cancer)
    Cancer related policies
    Research and clinical trials
    Market authorisation for innovative medicines
    New Pharmaceutical Legislative

    Address

    Head Office
    Brusselsesteenweg 11
    Meise 1860
    BELGIUM
    EU Office
    Brusselsesteenweg 11
    Meise 1860
    BELGIUM

    Website

    http://www.anticancerfund.org

  • People

    Total lobbyists declared

    2

    Employment timeLobbyists
    50%1
    25%1

    Lobbyists (Full time equivalent)

    0.75

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    https://www.icrpartnership.org/
    https://www.europeancancer.org/

    Member organisations

    International Cancer Research Partnership (https://www.icrpartnership.org/)
    European Society of Medical Oncology (https://www.esmo.org/)
    American Society of Clinical Oncology (https://www.asco.org/)
    Cure Drug Repurposing Collaboratory (https://c-path.org/programs/cdrc/)
    BIG (https://www.bigagainstbreastcancer.org/)
    BIG: Patient Partnership Initiative

  • Financial Data

    Interests represented

    Does not represent commercial interests

    Closed financial year

    Jan 2021 - Dec 2021

    Lobbying costs for closed financial year

    Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

    Total organisational budget in closed year

    1,635,952€

    Major funding types in closed year

    Donations

    Major contributions in closed year

    None declared

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    1. Public health related guidelines
    2. Member of the Repurposing Observatory Group (RepOG)
    3. Targeted EU Contact Program on cancer related policy:
    - Individual meetings with MEPs, Commissioners and Committee Members
    - Recommendations, feedback and reflections on how to strengthen Europe in the fight against cancer
    - Webinar to raise awareness among policymakers, researchers, physicians and patients of the potential of repurposed drugs in the treatment of cancer against the backdrop of the COVID-19 pandemic
    4. Stakeholder Contact Group EBCP

    Other activities

    Participation: Virtual Townhall Meeting for the Europe's Beating Cancer Plan (10 September 2020)
    Panelist invited by Olga Solomon: Pharmaceutical Strategy for Europe - Building a comprehensive pharmaceutical policy to address today’s challenges and tomorrow’s realities - DG SANTE Session - European Health Forum Gastein 2020 (1 October 2020)

  • Meetings

    Meetings

    None declared

Download this datacard